Dimensional Fund Advisors LP Grows Position in Innoviva, Inc. (NASDAQ:INVA)

Dimensional Fund Advisors LP increased its position in Innoviva, Inc. (NASDAQ:INVA) by 1.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,516,999 shares of the biotechnology company’s stock after purchasing an additional 66,295 shares during the period. Dimensional Fund Advisors LP owned 7.05% of Innoviva worth $72,454,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in Innoviva by 2.7% during the third quarter. PNC Financial Services Group Inc. now owns 46,109 shares of the biotechnology company’s stock worth $599,000 after acquiring an additional 1,234 shares in the last quarter. Pacer Advisors Inc. increased its holdings in shares of Innoviva by 119,140.3% during the fourth quarter. Pacer Advisors Inc. now owns 1,728,984 shares of the biotechnology company’s stock valued at $27,733,000 after acquiring an additional 1,727,534 shares in the last quarter. Boston Partners raised its position in shares of Innoviva by 10.2% in the 3rd quarter. Boston Partners now owns 393,470 shares of the biotechnology company’s stock worth $5,111,000 after purchasing an additional 36,313 shares during the last quarter. UBS Group AG boosted its stake in Innoviva by 223.8% in the 3rd quarter. UBS Group AG now owns 626,355 shares of the biotechnology company’s stock worth $8,136,000 after purchasing an additional 432,940 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Innoviva by 16.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 797,803 shares of the biotechnology company’s stock valued at $10,363,000 after purchasing an additional 115,009 shares during the last quarter. Institutional investors own 99.12% of the company’s stock.

Innoviva Trading Down 0.1 %

Innoviva stock opened at $15.78 on Friday. Innoviva, Inc. has a one year low of $12.22 and a one year high of $16.86. The business’s fifty day moving average is $15.20 and its 200 day moving average is $15.30. The stock has a market capitalization of $985.38 million, a PE ratio of 7.11 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 10.42 and a quick ratio of 9.17.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Thursday, February 29th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter. Innoviva had a net margin of 58.21% and a return on equity of 28.94%. The firm had revenue of $85.84 million for the quarter.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on INVA shares. StockNews.com raised shares of Innoviva from a “hold” rating to a “buy” rating in a report on Friday, March 29th. TheStreet raised Innoviva from a “c” rating to a “b-” rating in a research report on Thursday, February 29th.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.